Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent UpdatesBusiness Wire • 05/10/24
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual MeetingBusiness Wire • 05/07/24
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT MeetingBusiness Wire • 04/22/24
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent UpdatesBusiness Wire • 03/18/24
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical TrialBusiness Wire • 03/04/24
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical OfficerBusiness Wire • 01/16/24
Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 MillionBusiness Wire • 12/19/23